Tongfei Wu

This inventor holds 28 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 10 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Janssen Pharmaceutica Nv, Aligos Therapeutics, Inc., K.u. Leuven Research & Development. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tongfei Wu. Retrieved from https://idiyas.com/inventor/tongfei-wu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 6)

% Patents Active = 71.4

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 10 (Patent Applications = 15)

Average Co-Inventor Count = 7.1

ph-index = 3

Forward Citations = 50(Granted Patents)

Location History:

Turnhout, BE (2014 - 2015)
Leuven, BE (2011 - 2016)
Jette, BE (2015 - 2020)
Boortmeerbeek, BE (2021 - 2024)
Hever, BE (2021 - 2024)

Company Filing History:

16 out of 2,101

Janssen Pharmaceutica Nv

patents

5 out of 38

Aligos Therapeutics, Inc.

patents

5 out of 84

K.u. Leuven Research & Development

Janssen Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

PD-L1 Targeting

MALT1 Inhibitors

PRMT5 Inhibitors

Nucleoside Analogues

Gamma Secretase Modulators

Pharmaceutical Compositions

Spirobicyclic Analogues

Pyridine Derivatives

Carbanucleoside Analogues

Triazole Derivatives

Imidazole Derivatives

Bicyclic Heterocycles

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12534450 - Methods and compositions for targeting PD-L1 (2026-01-27),

2. 12428427 - Methods and compositions for targeting PD-L1 (2025-09-30),

3. 12404260 - Pyridine rings containing derivatives as MALT1 inhibitors (2025-09-02),

4. 12145961 - Spirobicyclic analogues (2024-11-19),

5. 12077521 - Pyrazole derivatives as MALT1 inhibitors (2024-09-03),

6. 12018015 - Methods and compositions for targeting PD-L1 (2024-06-25),

7. 11993614 - Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors (2024-05-28),

8. 11883367 - 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors (2024-01-30),

9. 11760764 - Methods and compositions for targeting PD-L1 (2023-09-19),

10. 11760761 - Methods and compositions for targeting PD-L1 (2023-09-19),

11. 11702441 - Spirobicyclic analogues (2023-07-18),

12. 11571437 - Methods of treating cancer using PRMT5 inhibitors (2023-02-07),

13. 11318157 - 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors (2022-05-03),

14. 11098062 - Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors (2021-08-24),

15. 11059850 - Spirobicyclic analogues (2021-07-13),

Title: Tongfei Wu: Innovator in Pharmaceutical Compounds

Introduction

Tongfei Wu, based in Hever, Belgium, is an accomplished inventor with a remarkable portfolio of 20 patents. His work primarily focuses on the development of novel pharmaceutical compounds that target various biological pathways. Wu's innovative contributions to the field have the potential to impact the treatment of several diseases.

Latest Patents

Among his most recent patents are the following notable inventions:

1. **Spirobicyclic Analogues** - This invention relates to novel spirobicyclic analogues of Formula (I), designed to function as PRMT5 inhibitors. The compounds offer valuable pharmaceutical applications, further elucidated by their formulations and potential use as medicaments.

2. **Pyrazole Derivatives as MALT1 Inhibitors** - This patent discloses various compounds, compositions, and methods aimed at treating conditions influenced by MALT1 modulation. The detailed structure represented by Formula (I) highlights the versatile applications of these compounds.

Career Highlights

Tongfei Wu has worked with prominent companies in the pharmaceutical industry, including Janssen Pharmaceutica and Aligos Therapeutics, Inc. His experience in these organizations has equipped him with essential knowledge and skills crucial for successful invention in the pharmaceutical domain.

Collaborations

During his career, Wu has collaborated with esteemed colleagues such as Lieven Meerpoel and Johannes Wilhelmus John F Thuring. This partnership has allowed for the melding of ideas and expertise, further advancing the development of innovative therapeutics.

Conclusion

Tongfei Wu is a significant contributor to the field of pharmaceuticals, with a robust collection of patents that demonstrate his dedication to innovation. His groundbreaking work on spirobicyclic analogues and pyrazole derivatives underscores the potential for innovative treatments that may revolutionize patient care. Wu's endeavors will undoubtedly inspire future research and development in medical science.

Profile summary based on public USPTO records.